Clinical Trial Update: A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating TQ-B3525 tablets in relapsed/refractory mantle cell lymphoma (MCL) is in progress, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• TQ-B3525

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Relapsed / Refractory Mantle Cell Lymphoma (MCL) | Phase 2 | Status: UNKNOWN